Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15153786rdf:typepubmed:Citationlld:pubmed
pubmed-article:15153786lifeskim:mentionsumls-concept:C0006142lld:lifeskim
pubmed-article:15153786lifeskim:mentionsumls-concept:C1516213lld:lifeskim
pubmed-article:15153786lifeskim:mentionsumls-concept:C0153690lld:lifeskim
pubmed-article:15153786lifeskim:mentionsumls-concept:C0297331lld:lifeskim
pubmed-article:15153786lifeskim:mentionsumls-concept:C0162491lld:lifeskim
pubmed-article:15153786pubmed:issue4lld:pubmed
pubmed-article:15153786pubmed:dateCreated2004-5-21lld:pubmed
pubmed-article:15153786pubmed:abstractTextDiagnosis and follow-up of bone metastases in breast cancer patients usually rely on symptoms and imaging studies. Tartrate-resistant acid phosphatase 5b (TRACP 5b) is a specific marker of osteoclasts and is herein proposed as a marker of bone metastasis in breast cancer patients. An immunoassay using a monoclonal antibody, 14G6, was used to measure the activity of serum TRACP 5b at pH 6.1 in 30 early breast cancer patients without bone metastasis and in 30 aged-matched breast cancer patients with bone metastasis. Another 60 normal volunteers were recruited as controls. Bone alkaline phosphatase (BAP), a traditional marker of bone turnover, was also measured in selected cases. The overall mean TRACP 5b activity in normal women was 2.83 +/- 1.1 U/l, and it increased with age. The mean TRACP 5b activity in early breast cancer patients did not differ from that of the normal group (2.93 +/- 0.64 vs. 2.83 +/- 1.1 U/l; p = 0.66), whereas it was significantly higher in breast cancer patients with bone metastasis (5.42 +/- 2.5 vs. 2.83 +/- 1.1 U/l; p < 0.0001). BAP activity was significantly higher in breast cancer patients with bone metastasis than in early breast cancer patients (p = 0.004). Serum TRACP 5b activity correlated well with BAP activity in breast cancer patients with bone metastasis (p < 0.0001), but not in normal individuals or in patients without bone metastasis. TRACP 5b activity can be considered a surrogate indicator of bone metastasis in breast cancer patients.lld:pubmed
pubmed-article:15153786pubmed:languageenglld:pubmed
pubmed-article:15153786pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15153786pubmed:citationSubsetIMlld:pubmed
pubmed-article:15153786pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15153786pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15153786pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15153786pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15153786pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15153786pubmed:statusMEDLINElld:pubmed
pubmed-article:15153786pubmed:issn1021-7770lld:pubmed
pubmed-article:15153786pubmed:authorpubmed-author:YamLung TLTlld:pubmed
pubmed-article:15153786pubmed:authorpubmed-author:HoChing-Liang...lld:pubmed
pubmed-article:15153786pubmed:authorpubmed-author:ChaoTsu-YiTYlld:pubmed
pubmed-article:15153786pubmed:authorpubmed-author:LeeSu-HueiSHlld:pubmed
pubmed-article:15153786pubmed:authorpubmed-author:ChenMary...lld:pubmed
pubmed-article:15153786pubmed:authorpubmed-author:JanckilaAntho...lld:pubmed
pubmed-article:15153786pubmed:copyrightInfoCopyright 2004 National Science Council, ROC and S. Karger AG, Basellld:pubmed
pubmed-article:15153786pubmed:issnTypePrintlld:pubmed
pubmed-article:15153786pubmed:volume11lld:pubmed
pubmed-article:15153786pubmed:ownerNLMlld:pubmed
pubmed-article:15153786pubmed:authorsCompleteYlld:pubmed
pubmed-article:15153786pubmed:pagination511-6lld:pubmed
pubmed-article:15153786pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:15153786pubmed:meshHeadingpubmed-meshheading:15153786...lld:pubmed
pubmed-article:15153786pubmed:meshHeadingpubmed-meshheading:15153786...lld:pubmed
pubmed-article:15153786pubmed:meshHeadingpubmed-meshheading:15153786...lld:pubmed
pubmed-article:15153786pubmed:meshHeadingpubmed-meshheading:15153786...lld:pubmed
pubmed-article:15153786pubmed:meshHeadingpubmed-meshheading:15153786...lld:pubmed
pubmed-article:15153786pubmed:meshHeadingpubmed-meshheading:15153786...lld:pubmed
pubmed-article:15153786pubmed:meshHeadingpubmed-meshheading:15153786...lld:pubmed
pubmed-article:15153786pubmed:meshHeadingpubmed-meshheading:15153786...lld:pubmed
pubmed-article:15153786pubmed:meshHeadingpubmed-meshheading:15153786...lld:pubmed
pubmed-article:15153786pubmed:meshHeadingpubmed-meshheading:15153786...lld:pubmed
pubmed-article:15153786pubmed:meshHeadingpubmed-meshheading:15153786...lld:pubmed
pubmed-article:15153786pubmed:meshHeadingpubmed-meshheading:15153786...lld:pubmed
pubmed-article:15153786pubmed:meshHeadingpubmed-meshheading:15153786...lld:pubmed
pubmed-article:15153786pubmed:meshHeadingpubmed-meshheading:15153786...lld:pubmed
pubmed-article:15153786pubmed:meshHeadingpubmed-meshheading:15153786...lld:pubmed
pubmed-article:15153786pubmed:meshHeadingpubmed-meshheading:15153786...lld:pubmed
pubmed-article:15153786pubmed:articleTitleTartrate-resistant acid phosphatase 5b as a serum marker of bone metastasis in breast cancer patients.lld:pubmed
pubmed-article:15153786pubmed:affiliationDivision of Hematology/Oncology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, ROC. j0607@ms6.hinet.netlld:pubmed
pubmed-article:15153786pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15153786pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15153786lld:pubmed